Target
mFOLFIRINOX
5 abstracts
Abstract
Comparison of prophylactic effects for chemotherapy-induced neutropenia between same-day vs next-day administration of pegteograstim in chemotherapy regimen composed of day 1 intensive myelosuppressive agent: A randomized phase III trial (CONCISE, KCSG PC22-11).Org: Hanyang University Seoul Hospital, Yangsan, South Korea, Uijeongbu St. Mary’s Hospital, Uijeongbu, South Korea, Dong-A University College of Medicine,
Abstract
Perioperative fuzuloparib plus mFOLFIRINOX for resectable pancreatic adenocarcinoma: A phase 1 study.Org: Pancreatic Disease Center, Shanghai Jiao Tong University School of Medicine,
Abstract
A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).Org: Clinical Research Alliance, LSU School of Medicine, CG Pharmaceuticals Inc.,
Abstract
Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505.Org: University of Cincinnati Medical Center, SWOG Statistical Center, University of Cincinnati College of Medicine, Fred Hutchinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA,
Abstract
Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer.Org: Northwestern University Robert H. Lurie Comprehensive Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center,